SPOTLIGHT: No new PML cases for Tysabri

October 12, 2007 — 6:59am ET

Watchdog endorses use of Tysabri for severe MS
After reintroduction, Tysabri builds patient base
New warning issued on Rituxan for lupus
FDA office rebukes plans to track Tysabri
NEJM publishes positive 2-year Tysabri data
FDA allows limited trial of Tysabri
ALSO NOTED: Altus files $115M IPO; Elan, Biogen find no new PML cases; Genentech discouraging Avastin for macular degeneration;
Biogen Idec, Elan plan to seek FDA's OK to resume Tysabri sales
Biogen, Elan report no new PML cases in Tysabri review
Tysabri scores positive results in Crohn's trial

Tools

Email
Print
Comment
Contact Author

As of September, there have been no new cases of the potentially fatal brain disease PML among patients taking Tysabri. The drug was pulled from the market last year after several patients taking the MS treatment developed PML. Release

Be the first to comment

Comments

Post new comment

Paid Research Reports

RNA therapy: the next big thing after monoclonal antibodies?
Biotech M&A Strategies: Deal assessments, trends and future prospects
The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
Sales Force Effectiveness
Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage

More Research Reports >>

Most Popular Stories

Featured Jobs

Webinars

Popular Topics

Events

SPOTLIGHT: No new PML cases for Tysabri

Related Stories

Comments

Post new comment

Paid Research Reports

THE FIERCEMARKETS NETWORK